Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Payables (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Payables for 5 consecutive years, with $520709.0 as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 65.98% to $520709.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $520709.0, a 65.98% decrease, with the full-year FY2025 number at $1.2 million, changed N/A from a year prior.
  • Payables was $520709.0 for Q4 2025 at Neuphoria Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.3 million in Q2 2023 to a low of $520709.0 in Q4 2025.
  • A 4-year average of $1.4 million and a median of $1.3 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: rose 17.23% in 2023, then plummeted 65.98% in 2025.
  • Neuphoria Therapeutics' Payables stood at $2.0 million in 2022, then increased by 17.23% to $2.3 million in 2023, then plummeted by 34.58% to $1.5 million in 2024, then tumbled by 65.98% to $520709.0 in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Payables are $520709.0 (Q4 2025), $1.4 million (Q3 2025), and $1.2 million (Q2 2025).